Multidisciplinary

Top Medical News
Tristan Manalac, 40 minutes ago
Administrating continuous positive airway pressure (CPAP) through a helmet (h-CPAP) device safely improves oxygenation in women with moderate-to-severe acute respiratory failure (ARF) due to the coronavirus disease 2019 (COVID-19), a recent study has found.
an hour ago
Supplements of Panax ginseng may help prevent metabolic diseases from developing by controlling blood pressure, as well as blood levels of glucose and lipids, reports a recent meta-analysis.
Elaine Soliven, 9 hours ago

Treatment with a higher dose of semaglutide led to significantly improved glucose metabolism outcomes in patients with overweight/obesity and type 2 diabetes (T2D) compared with a lower dose of semaglutide or placebo, according to the STEP* 2 trial presented at EASD 2021.

Roshini Claire Anthony, 15 hours ago

The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.

15 hours ago
In immunocompetent patients admitted at a community hospital, comorbidities such as advanced gastric cancer and atrophic gastritis (AG), as well as treatment with proton pump inhibitors (PPI), seem to aggravate the risk of developing oesophageal candidiasis (EC), a recent study has found.
Pearl Toh, 18 hours ago
The oral selective JAK1/2 inhibitor baricitinib significantly reduces the risk of death in critically ill COVID-19 patients who are on invasive mechanical ventilation (IMV) or ECMO*, when used in combination with standard care, according to the addendum study of the COV-BARRIER trial presented at IDWeek 2021.
Jairia Dela Cruz, 19 hours ago
Treatment with everolimus appears to have beneficial effects on recurrent thymic neuroendocrine neoplasia (NEN), particularly well-differentiated tumours, with patients having a low Ki-67 index more likely to have a better outcome with the drug, as shown in a small study.
Special Reports
Elvira Manzano, 24 Oct 2021
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
Pearl Toh, 23 Oct 2021
While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.
Roshini Claire Anthony, 20 Oct 2021

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

01 Oct 2021
During the recent EMPIRE SUMMIT, Professor Dr Chee Kok Han discussed the importance of an early, patient-centred,multi factorial approach in managing type 2 diabetes mellitus(T2DM). Specifically, Professor Chee highlighted the role ofempagliflozin (Jardiance®, Boehringer Ingelheim) in conferring cardiorenal protection to patients with T2DM.
01 Oct 2021
Psoriasis is characterised by well-circumscribed, erythematous, scaly plaques and can be categorised as eitherlocalised or generalised, depending on the severity of the disease and its impact on patients’ quality of life. The mainstay of treatment for localised disease includes topical therapy with corticosteroids, calcipotriene and coal tar products, while generalised psoriasis may require more advanced forms of treatment like phototherapy and systemic therapy. In this case study, Dr Preamala Gunabalasingam shares her clinical experience treating.2plaque psoriasis with a combined formulation of betamethasone dipropionate and calcipotriol monohydrate in a single spray foam (Enstilar® Foam, LEO Pharma). 
29 Sep 2021
Edoxaban 30 mg and 60 mg FC tab
29 Sep 2021
Isavuconazole 100 mg hard cap and 200 mg infusion conc
Conference Reports
Elaine Soliven, 27 Oct 2021

Treatment with a higher dose of semaglutide led to significantly improved glucose metabolism outcomes in patients with overweight/obesity and type 2 diabetes (T2D) compared with a lower dose of semaglutide or placebo, according to the STEP* 2 trial presented at EASD 2021.

Roshini Claire Anthony, 26 Oct 2021

The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.

Pearl Toh, 26 Oct 2021
The oral selective JAK1/2 inhibitor baricitinib significantly reduces the risk of death in critically ill COVID-19 patients who are on invasive mechanical ventilation (IMV) or ECMO*, when used in combination with standard care, according to the addendum study of the COV-BARRIER trial presented at IDWeek 2021.
Elvira Manzano, 24 Oct 2021
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
Pearl Toh, 23 Oct 2021
While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.
Roshini Claire Anthony, 23 Oct 2021

Patients who receive sacubitril-valsartan after an acute myocardial infarction (MI) have a similar health status, as determined by EQ-5D visual analog scale (VAS) score, compared with those who receive ramipril, according to results of a prespecified analysis of the PARADISE-MI trial presented at HFSA 2021.

Pearl Toh, 22 Oct 2021
The oral selective Janus kinase 3 (JAK3) inhibitor ritlecitinib effectively prevents hair loss in people with alopecia areata (AA) compared with placebo, according to the ALLEGRO study presented at EADV 2021.